Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Lexicon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 19, 2023 / 02:15PM GMT
Release Date Price: €4.1
Joey Stringer
Needham & Company - Moderator

Good morning, everyone. Thank you for joining the 22nd Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Lexicon Pharmaceuticals. Joining us today from the company is CEO, Lonnel Coats; CFO, Jeff Wade; and CMO, Craig Granowitz.

For those of you joining on the webcast, if you want to ask a question, you can do so by using the chat box feature at the bottom of your screen. So with that, we'll go ahead and get started.

Lonnel, Jeff, and Craig, thank you so much for joining us today.

Lonnel Coats
Lexicon Pharmaceuticals, Inc. - CEO and Director

Thanks, Joey.

Questions & Answers

Joey Stringer;Lonnel Coats<
Needham & Company - Moderator

So we'll get right into it with sotagliflozin. You have an upcoming US approval decision here next month. Any new updates you can provide us on that?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot